Gerald W. Prager
Impact in
- Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research top 2%
- Protease and Inhibitor Mechanisms
- Cancer Genomics and Diagnostics
Papers in
- Oncology 124
- Colorectal Cancer Treatments and Studies 60
- Pancreatic and Hepatic Oncology Research 35
- Cancer Treatment and Pharmacology 18
-
- Cancer Genomics and Diagnostics 34
Gerald W. Prager
157 papers receiving 3.4k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Oncology 1.7k
- Cancer Research 921
- Immunology and Allergy 228
- Pulmonary and Respiratory Medicine 802
- Pathology and Forensic Medicine 426
Countries citing papers authored by Gerald W. Prager
This map shows the geographic impact of Gerald W. Prager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald W. Prager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald W. Prager more than expected).
Fields of papers citing papers by Gerald W. Prager
This network shows the impact of papers produced by Gerald W. Prager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald W. Prager. The network helps show where Gerald W. Prager may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gerald W. Prager, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 2 | |
| 7 | 2023 | 1 | |
| 8 | Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 190 |
| 9 | 2023 | 5 | |
| 10 | 2023 | 5 | |
| 11 | Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2023 | 183 |
| 12 | 2022 | 13 | |
| 13 | 2022 | 0 | |
| 14 | 2020 | 3 | |
| 15 | 2020 | 7 | |
| 16 | 2020 | 15 | |
| 17 | 2020 | 2 | |
| 18 | 2020 | 12 | |
| 19 | 2013 | 56 | |
| 20 | 2007 | 61 |
About Gerald W. Prager
Gerald W. Prager is a scholar working on Oncology, Cancer Research, Immunology and Allergy, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 171 papers that have together received 3.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (60 papers), Pancreatic and Hepatic Oncology Research (35 papers), Cancer Genomics and Diagnostics (34 papers), Genetic factors in colorectal cancer (24 papers), Gastric Cancer Management and Outcomes (22 papers), Lung Cancer Treatments and Mutations (21 papers), Cancer Treatment and Pharmacology (18 papers) and Cell Adhesion Molecules Research (16 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (921 citations), Immunology and Allergy (228 citations), Pulmonary and Respiratory Medicine (802 citations) and Pathology and Forensic Medicine (426 citations). Gerald W. Prager has collaborated with scholars based in Austria, Germany and France. Frequent co-authors include Bernd R. Binder, Judit Mihaly, Matthias Unseld, Christoph Zielinski, Daniela Bianconi, Marina Poettler, Johannes M. Breuss, Élena Elez, Alexander Stein and Stefan Steurer. Their work appears in journals such as Journal of Clinical Oncology, ESMO Open, Annals of Oncology, Cancers and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.